---
title: "JINLING PHARM.: Olaratumab tablets approved to conduct Phase III clinical research"
description: "JINLING PHARM. announced that its subsidiary JINLING Pharmaceutical Factory has received approval from the National Medical Products Administration to conduct Phase III clinical research on Elagolix t"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/255750869.md"
published_at: "2025-09-03T09:18:02.000Z"
---

# JINLING PHARM.: Olaratumab tablets approved to conduct Phase III clinical research

> JINLING PHARM. announced that its subsidiary JINLING Pharmaceutical Factory has received approval from the National Medical Products Administration to conduct Phase III clinical research on Elagolix tablets. Elagolix tablets are a GnRH antagonist primarily used to treat moderate to severe pain associated with endometriosis. This drug has been included in the national "Second Batch of Encouraged Generic Drug List."

According to the Zhitong Finance APP, JINLING PHARM. (000919.SZ) announced that its subsidiary, Nanjing JINLING Pharmaceutical Factory (referred to as "JINLING Pharmaceutical Factory"), has received the clinical trial application acceptance notice for Elagolix from the National Medical Products Administration. Recently, JINLING Pharmaceutical Factory received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving the initiation of Phase III clinical research for Elagolix.

Elagolix is an oral gonadotropin-releasing hormone (GnRH) antagonist primarily used to treat moderate to severe pain associated with endometriosis. Elagolix is currently included in the national "Second Batch of Encouraged Generic Drug Catalog."

### Related Stocks

- [000919.CN - JINLING PHARM.](https://longbridge.com/en/quote/000919.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| New study finds early hormone replacement therapy reduces risk of osteoporosis and fractures for older women | A new study presented at the 2026 AAOS Annual Meeting reveals that early hormone replacement therapy (HRT) significantly | [Link](https://longbridge.com/en/news/277412093.md) |
| SSY Group's Respiratory Drug Approved for Production in China | SSY Group's Respiratory Drug Approved for Production in China | [Link](https://longbridge.com/en/news/277561555.md) |
| How can I systematically track high-win-rate wallet addresses on Polymarket? | The article discusses strategies for tracking high-win-rate wallet addresses on Polymarket, emphasizing the importance o | [Link](https://longbridge.com/en/news/277561416.md) |
| LESS NOISE, BETTER SIGNALS: HOW PHARMA CAN MEASURE IMPACT AS AI RESHAPES SEARCH | The article discusses the transformation of search in the pharmaceutical industry due to AI adoption, emphasizing the sh | [Link](https://longbridge.com/en/news/277470520.md) |
| Does RFK Jr. care that babies will needlessly die under his vaccination policies? | The article discusses the impact of Robert F. Kennedy Jr.'s vaccination policies, highlighting a resurgence of measles c | [Link](https://longbridge.com/en/news/277225914.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.